BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

Core Viewpoint - BioRestorative Therapies, Inc. has received patent approval in Australia for its innovative ThermoStem technology, which utilizes brown adipose-derived stem cells to address obesity and metabolic disorders, enhancing its competitive position in the regenerative medicine market [1][2][3] Group 1: Patent Approval and Technology - The Australian government has allowed Patent Application No. 2020265664, providing broad protection for BioRestorative's ThermoStem technology [1] - The patent covers a method for creating non-naturally occurring three-dimensional brown adipose-derived stem cell aggregates [1] - This patent strengthens BioRestorative's position in developing alternatives to GLP-1 drugs, which are rapidly growing in the therapeutic market [2][3] Group 2: Company Overview and Programs - BioRestorative focuses on developing therapeutic products using adult stem cells, with two main clinical programs targeting disc/spine disease and metabolic disorders [4] - The Disc/Spine Program includes BRTX-100, a cell therapy candidate for treating chronic lower back pain, currently in Phase 2 clinical trials [4] - The Metabolic Program, ThermoStem, aims to utilize brown adipose-derived stem cells to generate brown adipose tissue, which may enhance metabolic health and aid in weight loss [5] Group 3: BioCosmeceuticals - BioRestorative operates a BioCosmeceutical platform, offering a proprietary biologic serum designed to improve cosmetic appearance by reducing fine lines and wrinkles [6][7] - The company plans to expand its product offerings in the BioCosmeceuticals space through IND-enabling studies, aiming for FDA approvals [7]